Combination of Hydroxyurea and Verapamil for Refractory Meningiomas

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
CancerBrain CancerMeningioma
Interventions
DRUG

Hydroxyurea

Hydroxyurea inhibits DNA synthesis by inhibition of ribonucleotide diphosphate reductase and is a well-known drug used for the treatment of a number of tumor types including head and neck tumors and chronic myelogenous leukemia. It has also been used as an adjuvant for antiretroviral treatment for patients with HIV and as a treatment for polycythemia vera, essential thrombocythemia and sickle cell disease.

DRUG

Verapamil

Verapamil is another commonly used medication. It is used for the treatment of angina, hypertension, supraventricular arrhythmias, and migraine prophylaxis. Dosing with standard verapamil is 80-120 mg pox three times a day but the sustained release form can be given 120-480mg once or twice each day.

Trial Locations (1)

84112

Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT00706810 - Combination of Hydroxyurea and Verapamil for Refractory Meningiomas | Biotech Hunter | Biotech Hunter